1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO.TO
Thermo Fisher Scientific Inc.CA flagToronto Stock Exchange
23.30
CAD
+0.09
- -
338.84BMarket Cap
Thermo Fisher Scientific Inc.
TMO.TO
(Toronto Stock Exchange)

Recent

price

23.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.7
0.83
0.94
0.99
1.16
1.16
1.26
1.44
1.65
1.74
2.22
2.71
3.12
3.02
3.06
3.22
3.38
Revenue per Share
0.07
0.1
0.09
0.1
0.13
0.13
0.14
0.15
0.2
0.25
0.44
0.53
0.48
0.42
0.45
0.48
0.51
Basic EPS, GAAP
0.08
0.1
0.13
0.13
0.15
0.17
0.19
0.24
0.26
0.28
0.47
0.47
0.48
0.49
0.52
0.45
0.53
Free Cash Flow per Basic Share
- -
- -
0.01
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.03
0.03
0.04
0.04
0.05
0.05
Dividend per Share
39.25
40.49
43.26
46.57
51.31
53.42
54.75
63.32
68.6
74.42
86.99
103.42
112.62
120.87
130.22
141.96
142.48
Book Value per Share
1.15
-12.79
-13.47
-7.51
-30.98
-25.61
-34.97
-41.27
-31.68
-25.21
-10.64
-53.86
-37.54
-36.09
-30.99
-31.35
-56.14
Tangible Book Value per Share
14,808
13,982
13,358
13,230
14,621
14,640
14,496
14,504
14,761
14,687
14,540
14,467
14,393
14,173
14,026
13,843
13,696
Basic Weighted Avg Shares
10,393
11,559
12,510
13,090
16,890
16,965
18,274
20,918
24,358
25,542
32,218
39,211
44,915
42,857
42,879
44,557
46,336
Sales/Revenue/Turnover
12.01
11.66
12.5
12.89
11.28
14.45
14.49
14.61
15.74
16.37
24.5
26.08
18.94
17.08
18
18.2
18.29
Operating Margin (%)
746
860
984
1,000
1,685
1,688
1,758
2,033
2,267
2,277
2,325
2,592
3,381
3,406
3,108
2,780
2,942
Depreciation Expense
1,036
1,330
1,178
1,273
1,894
1,975
2,022
2,225
2,938
3,696
6,375
7,725
6,950
5,995
6,335
6,704
6,967
Net Income, GAAP
9.34
9.66
0.87
3.06
9.18
- -
- -
8.28
9.93
9.18
11.76
12.54
8.97
4.51
9.34
7.48
7.82
Effective Tax Rate (%)
9.96
11.51
9.42
9.73
11.22
11.64
11.06
10.64
12.06
14.47
19.79
19.7
15.47
13.99
14.77
15.05
15.04
Profit Margin (%)
2,425
1,709
2,742
6,755
1,190
1,595
2,155
2,373
4,478
5,696
11,653
6,677
8,219
10,577
8,805
13,518
8,296
Working Capital
2,031
5,755
7,031
9,500
12,352
11,420
15,372
18,873
17,719
17,076
19,107
32,333
28,909
31,308
29,061
35,852
39,181
LT Debt
15,361
15,038
15,465
16,856
20,548
21,350
21,540
25,413
27,586
29,675
34,517
40,977
44,148
46,842
49,672
53,536
52,808
Total Equity
6.44
6.16
6.96
6.57
5.54
- -
- -
6.63
7.44
8.1
13.47
13.57
10.05
8.73
8.62
8.65
8.64
Return on Invested Capital (%)
6.34
7.52
6.35
6.12
7.46
- -
- -
6.54
7.61
9.17
13.24
12.4
9.84
9.16
9.33
9.2
9.16
Return on Capital (%)
6.73
8.75
7.72
7.88
10.13
9.43
9.43
9.48
11.09
12.91
19.87
20.52
16.4
13.22
13.15
13.02
13.5
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,533
3,090
3,368
LT Borrowings
35,852
40,071
39,181
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
376
372
370
Market Capitalization
5,792
4,753
4,676

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
28,707
22,316
23,365
Cash, Cash Equivalents & STI
10,105
3,256
4,064
Accounts Receivable, Net
8,900
9,204
9,451
Inventories
5,425
5,496
5,627
Total Current Liabilities
15,189
14,621
15,069
Payables & Accruals
8,946
8,603
8,785
ST Debt
3,533
3,090
3,368
Deferred Revenue
2,710
2,928
2,918

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
9.28%
7.78%
Free Cash Flow
11.27%
-1.37%
-13.4%
Net Income, GAAP
15.16%
1.78%
5.82%
Sales/Revenue/Turnover
10.53%
7.13%
3.91%
Total Cash Common Dividend
10.36%
13.58%
9.09%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,345
10,541
10,598
11,395
42,879
2025
10,364
10,854
11,122
12,215
44,557
2026
11,005
11,994
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.11
0.12
0.13
0.45
2025
0.11
0.12
- -
0.14
0.48
2026
0.12
0.13
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
0.01
- -
0.01
0.05
2026
0.01
0.01
- -
- -
- -
Similar Companies
Precision System Science Co., Ltd. (7707.T)
Krsnaa Diagnostics Limited (KRSNAA.BO)
LungLife AI, Inc. (LLAI.L)
Healius Limited (HLS.AX)
Qiagen N.V. (QGEN)
GeneDx Holdings Corp. (WGS)
Business
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.